R. B. Edwards

development tool for human chronic lymphocytic leukemia Characterization of the TCL-1 transgenic mouse as a preclinical drug

Lisa L. Smith, M. Grever, J. Byrd, 2013 .

Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

Lisa L. Smith, M. Grever, J. Byrd, 2006, Blood.

Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol

M. Grever, A. Kinghorn, D. Jarjoura, 2012, Clinical Cancer Research.

Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells

M. Grever, J. Byrd, N. Heerema, 2011, The AAPS Journal.

Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Jeffrey S. Johnston, M. Grever, C. Hofmeister, 2013, Clinical Pharmacokinetics.

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.

Derek A. West, M. Grever, J. Byrd, 2009, Blood.

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

Derek A. West, Michael A. Freitas, M. Grever, 2010, PloS one.